Andrew Guggenhime - 18 Nov 2021 Form 4 Insider Report for Vaxcyte, Inc. (PCVX)

Role
President and CFO
Signature
/s/ Ron Metzger, Attorney-in-Fact
Issuer symbol
PCVX
Transactions as of
18 Nov 2021
Net transactions value
-$59,446
Form type
4
Filing time
22 Nov 2021, 15:58:17 UTC
Previous filing
22 Jul 2021
Next filing
21 Dec 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PCVX Common Stock Options Exercise $16,585 +3,100 +99% $5.35 6,225 18 Nov 2021 Direct F1
transaction PCVX Common Stock Sale $73,132 -2,985 -48% $24.50 3,240 18 Nov 2021 Direct F1, F2, F3
transaction PCVX Common Stock Sale $2,898 -115 -3.5% $25.20 3,125 18 Nov 2021 Direct F1, F2, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PCVX Stock Option (right to buy) Options Exercise $0 -3,100 -0.59% $0.000000 521,518 18 Nov 2021 Common Stock 3,100 $5.35 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes shares acquired under the Vaxcyte, Inc. employee stock purchase plan on November 17, 2020 of 1,562 shares and May 17, 2021 of 1,563 shares.
F2 The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
F3 The price reported is a weighted-average price. The shares were sold at prices ranging from $24.04 to $24.86. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F4 The price reported is a weighted-average price. The shares were sold at prices ranging from $25.08 to $25.28. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F5 1/4 of the shares subject to the option vested on May 1, 2021, and 1/48 of the shares vest monthly thereafter.